Verzenio Reduces Recurrence Risk for Certain Early-Stage Breast Cancers

Dr. Stephen Johnston is professor of breast cancer medicine and consultant medical oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London. At the European Society for Medical Oncology Virtual Congress 2020, Dr. Johnston presented results from the monarchE trial. This study compared treating people diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence with either standard hormonal therapy after surgery or two years of Verzenio (chemical name: abemaciclib) in addition to standard hormonal therapy. Listen to the podcast to hear Dr. Johnston explain: the characteristics that make early-stage hormone-receptor-positive, HER2-negative breast cancer have a high risk of recurrence an overview of the study and its early results side effects caused by Verzenio seen in the study the future of using Verzenio to treat early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence

There are no comments yet.

Please log in to write the first comment.